 iStockAnalyst (press release) | GE Healthcare (GE): FDA Approves Adreview For Cardiac Risk Evaluation In ... iStockAnalyst (press release) (NYSE: GE) said its unit GE Healthcare's AdreView (Iobenguane I 123 Injection) has received approval from the U.S. Food and Drug Administration (FDA) for cardiac risk evaluation in heart failure patients. AdreView is approved for the scintigraphic ... GE Healthcare Says FDA Approves Of A New Indication For AdreView |
